News
- Author:
- Sara Freeman
Publish date: December 17, 2013
Major finding: Between 4% and 8% of pan-negative melanomas harbor gene fusions involving BRAF and are sensitive to MEK inhibitor treatment.Data so...
News
- Author:
- Sara Freeman
Publish date: November 12, 2013
Major finding: Overall survival was 26.3 months in both study arms, and more events occurred in the cilenglitide arm than in the control arm (144 ...
News
- Author:
- Sara Freeman
Publish date: November 11, 2013
Major findings: The hazard ratios for overall survival were 0.78 (P = .007) in "high-risk" newly diagnosed patients and 0.85 (P = .174) in platinu...
News
- Author:
- Sara Freeman
Publish date: November 4, 2013
Major finding: Patients under age 65 (HR, 1.17) but not those aged 65 years and older (HR, 0.97) were more likely to die from cardiovascular cause...
News
- Author:
- Sara Freeman
Publish date: November 4, 2013
Major finding: Patients under age 65 (HR, 1.17) but not those aged 65 years and older (HR, 0.97) were more likely to die from cardiovascular cause...
News
- Author:
- Sara Freeman
Publish date: October 29, 2013
Major finding: Forty percent of patients were identified as having a molecular target for which an approved treatment could be given.Data source: ...
News
- Author:
- Sara Freeman
Publish date: October 25, 2013
Major finding: HT was associated with a 35% reduction in the risk for endometrial cancer (P = .007) when compared with placebo.Data source: The Wo...
News
- Author:
- Sara Freeman
Publish date: October 25, 2013
Major finding: HT was associated with a 35% reduction in the risk for endometrial cancer (P = .007) when compared with placebo.Data source: The Wo...
News
- Author:
- Sara Freeman
Publish date: October 25, 2013
Major finding: Results of the DCE-MRI analysis showed a decrease in tumor blood volume from a mean of 16% at the start of treatment to 7% at the e...
News
- Author:
- Sara Freeman
Publish date: October 25, 2013
Major findings: Overall survival in patients with high MET expression was 9.3 months with tivantinib plus erlotinib vs. 5.9 months for placebo plu...
News
- Author:
- Sara Freeman
Publish date: October 22, 2013
Major findings: Overall survival was a median of 12.6 months with combination treatment versus 10.3 months with docetaxel alone (HR = 0.83, P = .0...
News
- Author:
- Sara Freeman
Publish date: October 21, 2013
Major finding: Median overall survival was 11.2 months in patients treated with ipilimumab and 10 months for placebo (hazard ratio [HR] = 0.85, P ...
News
- Author:
- Sara Freeman
Publish date: October 18, 2013
Major finding: Mean PFS was 17.7 weeks vs.
News
- Author:
- Sara Freeman
Publish date: October 9, 2013
Major finding: The PD-L1 inhibitor was well tolerated and produced an objective response rate of 23% in heavily pretreated NSCLC patients.Data sou...
News
- Author:
- Sara Freeman
Publish date: October 9, 2013
Major finding: Progression-free survival was 66% in the group treated with the somatostatin analogue, compared with 22% in the placebo group (HR, ...
